Diabetes, Vol 37, Issue 8 1090-1095, Copyright © 1988 by American Diabetes Association

ARTICLES

Interaction of sulfonylureas with pancreatic beta-cells. A study with glyburide

FK Gorus, FC Schuit, PA In't Veld, W Gepts and DG Pipeleers
Department of Metabolism and Endocrinology, Vrije Universiteit Brussel, Belgium.

In this study on purified rat pancreatic beta-cells, we show that the second-generation sulfonylurea glyburide stimulates insulin release through a direct interaction with the beta-cells. During static incubations, 2 microM glyburide releases 0.16 pg insulin per beta-cell, which corresponds to a half-maximal glucose stimulation. This effect occurs independently from the glucose-recognition unit, being detectable at both nonstimulatory and stimulatory glucose concentrations and proceeding without alterations in the rate of glucose oxidation. The secretagogue action of glyburide appears not to be mediated through cAMP but is potentiated by cAMP-generating substances such as glucagon (10(-8) M; 0.31 pg insulin released per beta-cell). Its 10-fold higher potency in isolated islets is attributed to the markedly higher cAMP levels that are maintained in islet beta-cells under the influence of locally released glucagon. Perifused pancreatic beta-cells respond to glyburide with a biphasic insulin release. After removal of the drug, the cells continue to secrete insulin at the same rate for greater than or equal to 30 min. This prolonged secretory activity coincides with a cellular accumulation of the drug, primarily in association with membranes of secretory vesicles and mitochondria. Tolbutamide also stimulates insulin release from pure beta-cells, but it is less powerful on a molar basis and does not lead to a sustained hormone release after its removal from the extracellular medium. We conclude that the hypoglycemic action of glyburide is at least partly the result of a direct interaction with pancreatic beta-cells.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. Ling, Q. Wang, G. Stange, P. In't Veld, and D. Pipeleers Glibenclamide Treatment Recruits {beta}-Cell Subpopulation Into Elevated and Sustained Basal Insulin Synthetic Activity Diabetes, January 1, 2006; 55(1): 78 - 85. [Abstract] [Full Text] [PDF]

				K.-H. Park and T. Akaike Probing of Specific Binding of Synthetic Sulfonylurea with the Insulinoma Cell Line MIN6 J. Biochem., July 1, 2005; 138(1): 21 - 25. [Abstract] [Full Text] [PDF]

				K.-H. Park and T. Akaike Visualization of the Specific Interaction of Sulfonylurea-Incorporated Polymer with Insulinoma Cell Line MIN6 J. Biochem., February 1, 2004; 135(2): 179 - 183. [Abstract] [Full Text] [PDF]